| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTGFR |
| Uniprot No | P43088 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 0 |
| 活性数据 | MSMNNSKQLVSPAAALLSNTTCQTENRLSVFFSVIFMTVGILSNSLAIAILMKAYQRFRQKSKASFLLLASGLVITDFFGHLINGAIAVFVYASDKEWIRFDQSNVLCSIFGICMVFSGLCPLLLGSVMAIERCIGVTKPIFHSTKITSKHVKMMLSGVCLFAVFIALLPILGHRDYKIQASRTWCFYNTEDIKDWEDRFYLLLFSFLGLLALGVSLLCNAITGITLLRVKFKSQQHRQGRSHHLEMVIQLLAIMCVSCICWSPFLVTMANIGINGNHSLETCETTLFALRMATWNQILDPWVYILLRKAVLKNLYKLASQCCGVHVISLHIWELSSIKNSLKVAAISESPVAEKSAST |
| 分子量 | 40.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人PTGFR(前列腺素F受体)蛋白的3-4条虚构参考文献示例，格式符合要求：
1. **"Structural and Functional Characterization of Recombinant Human PTGFR in Lipid Signaling"**
- 作者：Abramovitz, M. et al.
- 摘要：通过昆虫细胞系统表达并纯化重组人PTGFR蛋白，分析其与前列腺素F2α的结合特性及下游Gq蛋白偶联的信号通路，揭示了受体激活的关键结构域。
2. **"Site-Directed Mutagenesis of PTGFR Reveals Residues Critical for Receptor Activation"**
- 作者：Okuda, Y. & Nishimura, K.
- 摘要：利用重组PTGFR突变体，鉴定第二胞内环(ICL2)中Arg³⁰¹和Tyr³⁰⁵为配体依赖性激活的必要氨基酸，为靶向药物设计提供依据。
3. **"Recombinant PTGFR in Disease Models: Implications for Ocular Hypertension Therapy"**
- 作者：Huang, L. et al.
- 摘要：构建重组PTGFR体外模型，评估小分子抑制剂对眼压调节的效应，发现化合物X可显著抑制受体介导的平滑肌收缩，具有治疗青光眼潜力。
4. **"Dynamic Interaction Between PTGFR and β-Arrestin Studied via Recombinant Protein Reconstitution"**
- 作者：Fujino, H. & Regan, J.W.
- 摘要：通过荧光标记的重组PTGFR蛋白，实时观测β-arrestin招募过程，阐明受体脱敏的动力学机制及病理状态下的异常调控。
注：以上文献及作者为虚构示例，实际研究中需检索真实数据库(如PubMed)获取可靠文献。
Prostaglandin F2-alpha receptor (PTGFR), also known as the prostaglandin F receptor, is a G protein-coupled receptor (GPCR) encoded by the *PTGFR* gene in humans. It belongs to the rhodopsin-like GPCR family and primarily binds prostaglandin F2α (PGF2α), a lipid mediator involved in diverse physiological processes. Structurally, PTGFR features seven transmembrane domains and signals through Gq proteins, activating downstream pathways like phospholipase C (PLC), which mobilizes intracellular calcium and modulates protein kinase C (PKC) activity.
This receptor plays critical roles in reproductive biology, including corpus luteum regression, ovarian function, and parturition. In the eye, PTGFR regulates intraocular pressure by mediating ciliary muscle contraction and extracellular matrix remodeling, making it a target for glaucoma therapies like latanoprost. Dysregulation of PTGFR signaling is linked to pathological conditions, including preterm labor, endometriosis, and cardiovascular disorders.
Recombinant human PTGFR protein is produced via heterologous expression systems (e.g., mammalian, insect cells) for structural and functional studies. Its purified form enables drug discovery, mechanism research, and exploration of receptor-ligand interactions. Researchers use it to study polymorphisms, mutations, and signaling crosstalk with other pathways, such as MAPK. By providing a controlled, high-purity protein source, recombinant PTGFR accelerates therapeutic development and deepens understanding of prostaglandin biology in health and disease.
×
